Combined Synopsis/SolicitationPosted Jul 30, 2026·Responses due Aug 13, 2026

6632--Integrated Microbiology Cost-Per-Test (CPT)

Veterans Affairs · 257-NETWORK CONTRACT OFFICE 17 (36C257)

Stage
Open solicitation
NAICS
334516
Value
Not stated
Solicitation
36C25726Q0805
Set-aside
None stated
PSC
6632
Place
Amarillo
Contact
Kathryn Prose (kathryn.prose@va.gov)
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 36C25726Q0805 in this department, oldest first.

Early notice
None posted
Solicitation
  • Jul 30, 2026 · this notice
    Combined Synopsis/Solicitation
Award
  • Aug 26, 2026
    Award Notice
    BIOMERIEUX INC · $950K
    Open

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Decide bid or no bid before the response deadline.
  • Look at the past winners for likely competitors and teaming partners.
  • Follow the opportunity to hear about amendments and the award.

What the notice says

This announcement constitutes the only solicitation. Solicitation No. 36C25726Q0805 is issued as a Request for Quotation (RFQ). This RFQ and all incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01. This requirement is being solicited as a Full and Open Competition. PRINCIPAL NAICS CODE: 334516 - Analytical Laboratory Instrument Manufacturing PRODUCT/SERVICE CODE: 6632 - Analysis Instruments, Medical Laboratory Use The Amarillo Veterans Affairs Healthcare System requires Integrated Microbiology instruments using the Cost-Per-Test (CPT) invoicing … (show all)

method supporting the Amarillo Veterans Affairs Medical Center and the Lubbock VA Community Based Outpatient Clinic. The instrumentation shall include automated blood culture detection systems at the Amarillo VA Medical Center and automated organism identification and antimicrobial susceptibility testing (ID/AST) systems supporting both Amarillo and Lubbock laboratory operations. The instrument shall be able to simultaneously perform the testing as described below and meet the performance characteristics for accuracy and precision as defined by the 1988 Clinical Laboratory Improvement Act (CLIA) and the Clinical and Laboratory Standards Institute (CLSI). Equipment must maintain, or preferably reduce, the number of workstations or overall labor required to accomplish the required testing by each laboratory. The proposed solution should support an integrated microbiology workflow between blood culture detection and ID/AST systems to minimize manual intervention and improve operational efficiency. Equipment shall be acquired for each of the clinical laboratories located at the AVAHCS facilities listed below. Blood culture instrumentation shall be required at the Amarillo VA Medical Center, which serves as the primary microbiology laboratory for AVAHCS. (1) Blood Culture Testing (Amarillo) - Estimated quantity is 2,400 blood culture sets across both sites annually. (2) Organism Identification / Susceptibility Testing Central Laboratory (Amarillo) - Gram-negative isolates: ~366 - Gram-positive isolates: ~514 - Other organisms (e.g., Haemophilus/Neisseria): minimal - Yeast identification: currently not performed; future capability of interest (including Candida auris) Satellite Site (Lubbock) - Gram-negative isolates: ~155 - Gram-positive isolates: ~105 (3) Antibiotic Information (a) Gram-Negative Organisms (including Enterobacterales): Amikacin, Ampicillin, Ampicillin/Sulbactam, Cefazolin, Cefoxitin, Ceftazidime, Ceftriaxone, Ciprofloxacin, Gentamicin, Levofloxacin, Meropenem, Piperacillin/Tazobactam, Tetracycline, Trimethoprim/Sulfamethoxazole (b) Urinary Pathogens (as applicable): Ampicillin, Ampicillin/Sulbactam, Cefazolin, Ceftriaxone, Ciprofloxacin, Gentamicin, Levofloxacin, Meropenem, Nitrofurantoin, Piperacillin/Tazobactam, Trimethoprim/Sulfamethoxazole (c) Pseudomonas aeruginosa: Amikacin, Aztreonam, Ceftazidime, Ciprofloxacin, Gentamicin, Levofloxacin, Meropenem, Piperacillin/Tazobactam (d) Gram-Positive Organisms (including Staphylococcus species): Ceftaroline, Clindamycin, Erythromycin, Levofloxacin, Linezolid, Oxacillin, Penicillin, Tetracycline, Trimethoprim/Sulfamethoxazole, Vancomycin (e) Enterococcus species: Ampicillin, Ciprofloxacin, Linezolid, Penicillin, Tetracycline, Vancomycin (f) Streptococcus species (including fastidious organisms): Ampicillin, Ceftriaxone, Clindamycin, Erythromycin, Levofloxacin, Penicillin, Tetracycline, Trimethoprim/Sulfamethoxazole, Vancomycin (g) Streptococcus pneumoniae: Ceftriaxone, Clindamycin, Erythromycin, Levofloxacin, Penicillin, Tetracycline, Trimethoprim/Sulfamethoxazole, Vancomycin Evaluation. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Technical Past Performance Price (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (c) Evaluation Approach. The Government will evaluate quotations using the comparative evaluation process outlined in RFO 12.203(c)(2), where quotations will be compared to one another to determine which provides the best benefit to the Government. The Government reserves the right to consider a quotation other than the lowest price that provides additional benefit(s). Quotations may exceed minimum requirements of the solicitation. The Government reserves the right to select a quotation that provides benefit to the Government that exceeds the minimum requirements of the solicitation but is not required to do so. Each response must meet the minimum requirements of the solicitation. This procurement is subject to the Free Trade Agreement (FTA) and includes FAR 52.225-5, Trade Agreements and FAR 52.225-6, Trade Agreement Certificate.

Who won similar work

28 award notices on SAM.gov in the last 24 months. Match: Same office, same NAICS 334516.

WinnerAwardsValueLast
ABBOTT LABORATORIES INC. · $ABT5$7.6MOct 1, 2026
BECKMAN COULTER, INC5$5.8MJan 28, 2026
POLYMEDCO CANCER DIAGNOSTIC PRODUCTS LLC2$2.5MNov 19, 2025
AGILENT TECHNOLOGIES INC · $A2$1.8MAug 24, 2026
WERFEN USA LLC2$1.6M + 1 sharedOct 14, 2026
TOSOH BIOSCIENCE, INC.1$3.0MNov 10, 2025
BECTON, DICKINSON AND COMPANY · $BDX1$1.3MAug 2, 2025
BRANCH MEDICAL LLC · $GMED1$900KOct 28, 2025
CEPHEID SUNNYVALE 940891$333KMay 15, 2026
GOVERNMENT SCIENTIFIC SOURCE INC1$271KFeb 18, 2026

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in.

Latest awards

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (5 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • $72K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 5 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards.

  • 4 of the past winners are listed companies
  • 0 insider buys and 7 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.